Page values for "Carvedilol"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Carvedilol
brand	`String`	Coreg, Coreg CR
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Beta blockers\|Beta blocker (non-selective • with alpha-1 antagonism)]] • [[:Category:Antihypertensives\|Antihypertensive]] • [[:Category:Heart failure medicines\|Heart failure medicine]]
mechanism	`String`	'"`UNIQ--vote-00000015-QINU`"' CYP2D6 metabolism produces stereoselective clearance; CYP2D6 poor metabolizers have higher plasma exposure and may need lower doses'"`UNIQ--ref-00000016-QINU`"'.
uses	`String`	'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"'
starting_dose	`String`	Heart failure: 3.125 mg PO BID, doubling every 2 weeks as tolerated to target 25 mg BID (50 mg BID if >85 kg). Hypertension: 6.25 mg PO BID, titrate to 25 mg BID
preparations	`String`	IR tablets 3.125, 6.25, 12.5, 25 mg; Coreg CR capsules 10, 20, 40, 80 mg (once-daily)
fda_max	`String`	50 mg BID in heart failure (or once-daily equivalent CR); 25 mg BID in hypertension
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Antihypertensive effect within 1 week; heart-failure mortality benefit accrues over months of titration
duration	`String`	~12 hours (IR); 24 hours (CR)
halflife	`String`	7-10 hours'"`UNIQ--ref-0000001B-QINU`"'
bioavailability	`String`	~25-35% (extensive first-pass), increased by food which slows absorption and reduces orthostatic risk'"`UNIQ--ref-0000001C-QINU`"'
pregnancy	`String`	Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	[[USLegal:Prescription only\|Rx-only]] in US